New China GCP To Be Issued Soon


2021-11-10

As a member of IMDRF (International Medical Device Regulators Forum), China is actively leading and participating in the formulation of relevant regulatory documents for international medical devices. Since 2019, NMPA has initiated to amend current China GCP (Good Clinical Practice), and in this May, NMPA collected public opinions on the draft of new China GCP.

Major amendments in GCP are listed as below:

Although new amendments in GCP are conductive to clinical trial in China, the requirements of clinical trial following GCP have always been enhanced. The least burdensome clinical approach is the most critical issue for China entry plan related to cost and time.

Brady knows the least burdensome clinical approach whether you are marking clinical strategic plans, launching pre-market or post-market clinical trials, writing a CER to meet country-specific requirements, or collecting real-world data to support your submission. Reach out to BradyKnows for the least burdensome clinical approach via info@inspirativemed.com